Glivec's copy products and compulsory enforcement

Published: 2002-11-07 06:57:00

Updated: 2002-11-07 06:57:00

As the Korean leukemia patients group continued to make their struggle for lowering the reimbursed price of Glivec after discontinuing the pricing negotiation with Novartis Korea, the Korean government's decision on the compulsory enforcement has emerged as a critical issue.

In situation where...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK